CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:RCMNet: A deep learning model assists CAR-T therapy for leukemia.
RCMNet: A deep learning model assists CAR-T therapy for leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
急性白血病是一种死亡率很高的血液癌症。目前的治疗方法包括骨髓移植、支持治疗和化疗。尽管可以获得令人满意的疾病缓解,但复发风险仍然很高。
因此,迫切需要新的治疗方法。CAR-T(CAR-T)疗法已成为治疗和治愈急性白血病的一种有前景的方法。为了发挥CAR-T 细胞疗法对血液疾病的治疗潜力,可靠的细胞形态学识别至关重要。
然而,由于CAR-T 细胞与其他血细胞表型相似,其识别是一个巨大挑战。为应对这一重大临床挑战,我们首先构建了一个包含500张染色后原始显微镜图像的CAR-T 数据集。随后,我们创建了一个名为RCMNet(ResNet18 with Convolutional Block Attention Module and Multi-Head Self-Attention)的新型集成模型,该模型结合了卷积神经网络(CNN)和Transformer。该模型在公开数据集上显示出99.63%的top-1准确率。与既往报道相比,我们的模型在图像分类方面取得了令人满意的结果。尽管在CAR-T 细胞数据集上测试时观察到不错的表现,但这归因于数据集规模有限。对RCMNet采用迁移学习后,最高达到83.36%的准确率,高于其他最先进的模型。
本研究评估了RCMNet在大型公开数据集上的有效性,并将其转化应用于临床数据集以用于诊断应用。
Acute leukemia is a type of blood cancer with a high mortality rate. Current therapeutic methods include bone marrow transplantation, supportive therapy, and chemotherapy. Although a satisfactory remission of the disease can be achieved, the risk of recurrence is still high.
Therefore, novel treatments are demanding. Chimeric antigen receptor-T (CAR-T) therapy has emerged as a promising approach to treating and curing acute leukemia. To harness the therapeutic potential of CAR-T cell therapy for blood diseases, reliable cell morphological identification is crucial. Nevertheless, the identification of CAR-T cells is a big challenge posed by their phenotypic similarity with other blood cells. To address this substantial clinical challenge, herein we first construct a CAR-T dataset with 500 original microscopy images after staining.
Following that, we create a novel integrated model called RCMNet (ResNet18 with Convolutional Block Attention Module and Multi-Head Self-Attention) that combines the convolutional neural network (CNN) and Transformer. The model shows 99. 63% top-1 accuracy on the public dataset. Compared with previous reports, our model obtains satisfactory results for image classification.
Although testing on the CAR-T cell dataset, a decent performance is observed, which is attributed to the limited size of the dataset. Transfer learning is adapted for RCMNet and a maximum of 83. 36% accuracy is achieved, which is higher than that of other state-of-the-art models.
This study evaluates the effectiveness of RCMNet on a big public dataset and translates it to a clinical dataset for diagnostic applications.
MEMBER ACCOUNT
登录成功会直接打开下一页。